Wille-Jørgensen P, et al. - In this randomized clinical trial that involved two thousand, five hundred nine patients with stage II or III colorectal cancer, the researchers analyzed overall mortality, colorectal cancer–specific mortality, and colorectal cancer–specific recurrence rates among patients with stage II or III colorectal cancer who were randomized after curative surgery to 2 alternative schedules for follow-up testing with computed tomography and carcinoembryonic antigen. Researchers reported that follow-up testing with computed tomography and carcinoembryonic antigen more frequently compared with less frequently did not result in a significant rate reduction in 5-year overall mortality or colorectal cancer–specific mortality among patients with stage II or III colorectal cancer.